JMPWA
NBIX icon

JP Morgan Private Wealth Advisors’s Neurocrine Biosciences NBIX Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$876K Sell
7,789
-174
-2% -$18.3K ﹤0.01% 1029
2023
Q2 		$751K Sell
7,963
-3,057
-28% -$299K ﹤0.01% 871
2023
Q1 		$1.12M Sell
11,020
-49
-0.4% -$5.1K ﹤0.01% 1119
2022
Q4 		$1.32M Buy
11,069
+113
+1% +$13.2K ﹤0.01% 1022
2022
Q3 		$1.16M Sell
10,956
-207
-2% -$21K ﹤0.01% 1061
2022
Q2 		$1.09M Buy
11,163
+311
+3% +$28.7K ﹤0.01% 1102
2022
Q1 		$1.02M Buy
10,852
+4,190
+63% +$355K ﹤0.01% 1216
2021
Q4 		$567K Sell
6,662
-2,413
-27% -$222K ﹤0.01% 1500
2021
Q3 		$870K Buy
9,075
+1,373
+18% +$130K ﹤0.01% 1279
2021
Q2 		$750K Buy
7,702
+1,672
+28% +$160K ﹤0.01% 1326
2021
Q1 		$586K Sell
6,030
-2,180
-27% -$229K ﹤0.01% 1250
2020
Q4 		$787K Sell
8,210
-26
-0.3% -$2.51K ﹤0.01% 1096
2020
Q3 		$792K Buy
8,236
+849
+11% +$98.2K ﹤0.01% 976
2020
Q2 		$901K Buy
7,387
+456
+7% +$50.4K ﹤0.01% 851
2020
Q1 		$600K Buy
6,931
+4,083
+143% +$400K ﹤0.01% 870
2019
Q4 		$306K Buy
2,848
+293
+11% +$30.7K ﹤0.01% 1232
2019
Q3 		$230K Sell
2,555
-8,626
-77% -$806K ﹤0.01% 1293
2019
Q2 		$944K Buy
+11,181
New +$918K 0.01% 771
2018
Q4 		– Sell
-23,491
Closed -$2.89M – 1545
2018
Q3 		$2.89M Sell
23,491
-188
-0.8% -$21.3K 0.01% 549
2018
Q2 		$2.33M Buy
23,679
+6
+0% +$537 0.01% 571
2018
Q1 		$1.96M Buy
23,673
+62
+0.3% +$5.24K 0.01% 488
2017
Q4 		$1.83M Sell
23,611
-81
-0.3% -$5.53K 0.01% 503
2017
Q3 		$1.45M Buy
23,692
+60
+0.3% +$3.17K 0.01% 534
2017
Q2 		$1.09M Buy
23,632
+1
+0% +$49 0.01% 597
2017
Q1 		$1.02M Buy
23,631
+231
+1% +$9.9K 0.01% 621
2016
Q4 		$906K Hold
23,400
– – 0.01% 620
2016
Q3 		$1.19M Sell
23,400
-2,623
-10% -$131K 0.01% 550
2016
Q2 		$1.18M Sell
26,023
-589
-2% -$27.1K 0.01% 552
2016
Q1 		$1.05M Sell
26,612
-62
-0.2% -$2.46K 0.01% 548
2015
Q4 		$1.51M Sell
26,674
-7,530
-22% -$383K 0.02% 434
2015
Q3 		$1.36M Sell
34,204
-6,071
-15% -$293K 0.02% 409
2015
Q2 		$1.92M Sell
40,275
-1,985
-5% -$84.2K 0.02% 374
2015
Q1 		$1.68M Sell
42,260
-9,740
-19% -$348K 0.02% 410
2014
Q4 		$1.16M Hold
52,000
– – 0.01% 496
2014
Q3 		$815K Hold
52,000
– – 0.01% 560
2014
Q2 		$771K Hold
52,000
– – 0.01% 461
2014
Q1 		$837K Buy
+52,000
New +$889K 0.02% 439

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Private Wealth Advisors's NBIX Position: Q3 2023 in Review

JP Morgan Private Wealth Advisors reduced its Neurocrine Biosciences (NBIX) stake by 2.2% in Q3 2023, selling an estimated $18.3K and leaving 7,789 shares worth $876K. The position accounts for ﹤0.01% of the portfolio, ranked #1029.

JP Morgan Private Wealth Advisors first reported a position in NBIX in Q1 2014 and has held it in 37 quarters since. The position peaked at $2.89M in Q3 2018. 512 funds tracked by Wall St. Rank hold NBIX as of Q3 2023.

  • JP Morgan Private Wealth Advisors held 7,789 shares of Neurocrine Biosciences worth $876K as of Q3 2023.
  • JP Morgan Private Wealth Advisors sold 174 Neurocrine Biosciences shares in Q3 2023, an estimated $18.3K.
  • Neurocrine Biosciences made up ﹤0.01% of JP Morgan Private Wealth Advisors's portfolio in Q3 2023, its #1029 holding.
  • JP Morgan Private Wealth Advisors first reported a position in Neurocrine Biosciences in Q1 2014 and has held it in 37 quarters since.
  • JP Morgan Private Wealth Advisors's Neurocrine Biosciences position peaked at $2.89M in Q3 2018.
  • 512 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2023.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.